Electra Therapeutics (NASDAQ:ETRA) Research Coverage Started at HC Wainwright

HC Wainwright began coverage on shares of Electra Therapeutics (NASDAQ:ETRA) in a report released on Monday morning, MarketBeat.com reports. The firm issued a buy rating and a $30.00 target price on the stock. HC Wainwright also issued estimates for Electra Therapeutics’ Q3 2026 earnings at ($0.56) EPS, Q4 2026 earnings at ($0.53) EPS, FY2026 earnings at ($3.17) EPS, Q1 2027 earnings at ($0.55) EPS, Q2 2027 earnings at ($0.60) EPS, Q3 2027 earnings at ($0.64) EPS, Q4 2027 earnings at ($0.70) EPS and FY2027 earnings at ($2.48) EPS.

Other equities analysts have also issued reports about the stock. Evercore initiated coverage on shares of Electra Therapeutics in a research report on Tuesday, October 13th. They set an “outperform” rating and a $36.00 price target for the company. Jefferies Financial Group began coverage on shares of Electra Therapeutics in a research note on Tuesday, October 13th. They set a “buy” rating and a $32.00 price objective for the company. Wall Street Zen raised shares of Electra Therapeutics to a “hold” rating in a report on Saturday, September 26th. TD Cowen initiated coverage on shares of Electra Therapeutics in a report on Tuesday, October 13th. They issued a “buy” rating on the stock. Finally, Zacks Research upgraded shares of Electra Therapeutics to a “hold” rating in a research note on Wednesday, October 14th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Electra Therapeutics has a consensus rating of “Buy” and a consensus price target of $33.50.

Electra Therapeutics Stock Up 5.4%

Shares of NASDAQ ETRA opened at $8.98 on Monday. Electra Therapeutics has a 52 week low of $8.26 and a 52 week high of $15.50.

Insider Transactions at Electra Therapeutics

In related news, Director Orbimed Advisors Llc acquired 1,333,333 shares of Electra Therapeutics stock in a transaction on Monday, September 21st. The stock was acquired at an average price of $15.00 per share, for a total transaction of $19,999,995.00. Following the purchase, the director owned 5,126,891 shares of the company’s stock, valued at approximately $76,903,365. This represents a 35.15% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Carl Gordon acquired 1,333,333 shares of the firm’s stock in a transaction dated Monday, September 21st. The stock was bought at an average cost of $15.00 per share, with a total value of $19,999,995.00. Following the acquisition, the director owned 5,126,891 shares in the company, valued at approximately $76,903,365. This trade represents a 35.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.

More Electra Therapeutics News

Here are the key news stories impacting Electra Therapeutics this week:

• Positive Sentiment: HC Wainwright expects Electra’s losses to narrow over time, forecasting fiscal 2026 EPS of -$3.17 and fiscal 2027 EPS of -$2.48, compared with the current full-year consensus estimate of -$3.55. The improving loss outlook supports the firm’s bullish rating and price target.
• Neutral Sentiment: The analyst projects continued quarterly losses, including EPS of -$0.56 in Q3 2026, -$0.53 in Q4 2026, and between -$0.55 and -$0.70 per share across the four quarters of 2027. These estimates indicate that Electra remains an early-stage, loss-making biotechnology company.
• Negative Sentiment: Despite the expected improvement, the forecasts do not anticipate profitability through fiscal 2027. Investors remain exposed to the risks typically associated with development-stage biotechnology companies, including ongoing cash burn and the need for successful clinical or commercial progress.

Electra Therapeutics Company Profile

Electra Therapeutics, Inc (NASDAQ: ETRA) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate the immune system. The company’s research is directed toward selectively influencing immune-cell activity to address serious diseases, including cancer and autoimmune conditions.

Electra Therapeutics is advancing a pipeline of investigational medicines based on its immune-cell modulation approach. Its programs are intended to improve the body’s ability to recognize, control, or eliminate disease-associated cells while limiting effects on healthy tissue.